Stock AZN ASTRAZENECA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 11:35:09 2024-04-26 am EDT 		5-day change 1st Jan Change
11,988 GBX -0.32% Intraday chart for AstraZeneca PLC +9.52% +13.09%
Apr. 26 ASTRAZENECA : DZ Bank sticks Neutral ZD
Apr. 26 ASTRAZENECA : UBS keeps a Sell rating ZD

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 132,331 131,461 181,878 210,243 209,128 231,480 - -
Enterprise Value (EV) 1 144,340 143,328 206,261 233,166 231,638 251,156 244,845 238,051
P/E ratio 97.9 x 41 x 1,468 x 64.3 x 35.4 x 27.2 x 22.9 x 20.3 x
Yield 2.78% 2.8% 2.44% 2.14% 2.15% 2.09% 2.18% 2.27%
Capitalization / Revenue 5.43 x 4.94 x 4.86 x 4.74 x 4.57 x 4.53 x 4.23 x 4.01 x
EV / Revenue 5.92 x 5.38 x 5.51 x 5.26 x 5.06 x 4.91 x 4.47 x 4.12 x
EV / EBITDA 21.6 x 17.2 x 27.2 x 25.2 x 17.1 x 14.1 x 12.3 x 11 x
EV / FCF 72.5 x 37.3 x 42.3 x 26.7 x 25.8 x 28 x 20.8 x 17.3 x
FCF Yield 1.38% 2.68% 2.36% 3.74% 3.88% 3.57% 4.81% 5.78%
Price to Book 10 x 8.41 x 4.24 x 5.67 x 5.38 x 5.66 x 4.84 x 4.43 x
Nbr of stocks (in thousands) 1,311,913 1,312,660 1,549,159 1,549,528 1,549,926 1,550,231 - -
Reference price 2 100.9 100.1 117.4 135.7 134.9 149.3 149.3 149.3
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 24,384 26,617 37,417 44,351 45,811 51,084 54,665 57,745
EBITDA 1 6,686 8,311 7,586 9,237 13,580 17,787 19,973 21,671
EBIT 1 6,436 7,340 9,928 13,350 14,534 16,739 18,957 20,662
Operating Margin 26.39% 27.58% 26.53% 30.1% 31.73% 32.77% 34.68% 35.78%
Earnings before Tax (EBT) 1 1,548 3,916 -265 2,501 6,899 10,738 12,914 14,270
Net income 1 1,335 3,196 112 3,288 5,961 8,613 10,235 11,643
Net margin 5.47% 12.01% 0.3% 7.41% 13.01% 16.86% 18.72% 20.16%
EPS 2 1.030 2.440 0.0800 2.110 3.810 5.486 6.524 7.362
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,965 11,787 13,765
FCF margin 8.16% 14.42% 13.02% 19.65% 19.61% 17.55% 21.56% 23.84%
FCF Conversion (EBITDA) 29.76% 46.18% 64.22% 94.37% 66.16% 50.4% 59.02% 63.52%
FCF Conversion (Net income) 149.06% 120.09% 4,350% 265.12% 150.71% 104.08% 115.17% 118.22%
Dividend per Share 2 2.800 2.800 2.870 2.900 2.900 3.119 3.250 3.392
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - 12,011 - 11,390 10,771 - 10,982 11,207 - 10,879 11,416 11,492 12,024 12,679 12,632 12,901 13,602 12,820 13,395
EBITDA 1 - - - 1,900 - 2,187 1,896 - 2,579 2,574 - - 3,732 - - - 4,602 4,711 6,276 - -
EBIT 1 - - - 3,318 - 3,961 3,365 - 3,413 2,610 - 3,946 4,291 3,545 2,752 4,310 4,514 4,302 3,735 - -
Operating Margin - - - 27.62% - 34.78% 31.24% - 31.08% 23.29% - 36.27% 37.59% 30.85% 22.89% 33.99% 35.74% 33.35% 27.46% - -
Earnings before Tax (EBT) 1 - - - -636 - 553 247 - 922 778 - 2,262 2,088 1,652 897 2,800 2,489 2,959 3,074 - -
Net income 1 - - - -347 - 386 360 - 1,640 901 - 1,803 1,818 1,378 959 2,179 2,396 2,337 2,463 - -
Net margin - - - -2.89% - 3.39% 3.34% - 14.93% 8.04% - 16.57% 15.93% 11.99% 7.98% 17.19% 18.97% 18.11% 18.11% - -
EPS 2 - - - -0.2200 - 0.2500 0.2300 - 1.050 0.5800 - 1.160 1.170 0.8900 0.6200 1.410 1.537 1.503 1.584 - -
Dividend per Share 2 0.9000 1.900 0.9000 1.970 1.970 - 0.9300 0.9300 - 1.970 1.970 - 0.9300 - 1.970 - 0.8775 0.7750 1.422 0.8750 0.8750
Announcement Date 7/30/20 2/11/21 7/29/21 2/10/22 2/10/22 4/29/22 7/29/22 7/29/22 11/10/22 2/9/23 2/9/23 4/27/23 7/28/23 11/9/23 2/8/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,009 11,867 24,383 22,923 22,510 19,778 13,389 6,571
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.796 x 1.428 x 3.214 x 2.482 x 1.658 x 1.112 x 0.6704 x 0.3032 x
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,965 11,787 13,765
ROE (net income / shareholders' equity) 35.6% 36.7% 27.5% 27.2% 29.8% 28.8% 30.3% 30.6%
ROA (Net income/ Total Assets) 2.19% 4.99% 8.77% 3.26% 11.5% 9.74% 10.9% 11.5%
Assets 1 61,015 64,053 1,277 100,924 51,935 88,408 94,308 101,271
Book Value Per Share 2 10.10 11.90 27.70 23.90 25.10 26.40 30.80 33.70
Cash Flow per Share 2 2.280 3.660 4.180 6.290 6.620 8.880 10.40 12.10
Capex 1 979 961 1,091 1,091 1,361 2,311 2,097 2,039
Capex / Sales 4.01% 3.61% 2.92% 2.46% 2.97% 4.52% 3.84% 3.53%
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for AstraZeneca PLC

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3 USD
Average target price
164.4 USD
Spread / Average Target
+10.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 233B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 653B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 296B
NOVARTIS AG Stock Novartis AG
+5.46% 201B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 193B
AMGEN INC. Stock Amgen Inc.
-6.26% 144B
PFIZER, INC. Stock Pfizer, Inc.
-11.77% 143B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. Financials AstraZeneca PLC